Gene Therapy Partnering Terms and Agreements Market Research Reports, Inc. has announced the addition of "Gene Therapy Partnering Terms and Agreements" research report to their offering. See more at- http://mrr.cm/ZMF. By: Market Research Reports, Inc. … Continue reading →

MILAN (TheStreet) -- Two patients with a serious, inherited blood disorder have been able to stop blood transfusions following a single treatment with an experimental gene therapy developed by Bluebird Bio (BLUE), according to new but preliminary data presented Saturday. The two patients reported on today have beta-thalassemia (B-thal), a disease caused by a missing or defective gene which prevents oxygen-carrying hemoglobin from functioning properly. The BlueBird therapy, known as LentiGlobin, replaces the defective gene with one that is fully functional. Beta-thalassemia patients suffer from chronic anemia and typically require regular and lifelong blood transfusions. Following a single infusion of Bluebird's LentiGlobin gene therapy, the two B-thal patients started producing functional hemoglobin and within 10 and 12 days, respectively, were able to halt blood transfusions. The patients have now been blood-transfusion independent for approximately 6 and 3 months, respectively, according to Bluebird Chief Medical Officer David Davidson. The data are being presented Saturday at the European Hematology Association annual meeting. "Following the [gene] transplant, we're seeing near normal levels of hemoglobin," said Davidson. "These early results far exceeded our expectations." Bluebird only has limited data on two patients and the study, conducted in France, continues with seven B-thal patients expected … Continue reading →